SPINDLIN1, a new member of the SPIN/SSTY gene family, was first identified as a gene highly expressed in ovarian cancer cells. We have previously shown that it is involved in the process of spindle organization and chromosomal stability, and plays a role in the development of cancer.
a result of phosphorylation modification, in a cell cycle-dependent fashion. In our earlier report on ovarian cancer cells, we identified human gene SPINDLIN1 as a new member of the SPIN/SSTY gene family. This family is involved in gametogenesis, and the expression of genes in this family can be detected in early embryos (2) . We found that SPINDLIN1 is highly expressed in human early embryonic tissues, including ovary and kidney. However, the expression level of SPINDLIN1 is dramatically decreased and cannot be detected in any embryonic tissues at 8 months. SPINDLIN1 is highly expressed in many kinds of malignant tumor tissues, including ovarian tumors, non-small cell lung cancers and some hepatic carcinomas (3).
In addition, NIH3T3 cells with ectopic expression of SPINDLIN1 form colonies in culture and tumors in nude mice, suggesting this gene's oncogenic potential (4) . We also reported that SPINDLIN1, a nuclear protein, is relocated during cell mitosis and dynamically distributes along mitotic spindle tubulin, indicating that SPINDLIN1 is a novel spindle protein (5) . We also found that ectopic expression of SPINDLIN1 induces cell cycle delay in metaphase and causes chromosome instability (5, 6) .
The WNT signaling pathway regulates cell fate in a large number of developmental processes and differentiation during embryogenesis (7, 8) . In addition, the vital role of this pathway in tumorigenesis arouses great research interest (9) (10) (11) . β-CATENIN, stabilized by activation of WNT signaling, is translocated into the nucleus to form nuclear complexes with transcription factors of the TCF/LEF family and subsequently activates several downstream effectors such as C-MYC and CYCLIN D1. These target genes are known to regulate the cell cycle and contribute to the oncogenic phenotype (12) . We believed that uncovering the regulators of WNT/TCF-4 signaling would give rise to a better understanding of the potential mechanisms of carcinogenesis. Human AURORA-A is commonly amplified in epithelial malignant tumors, and more than 50% of ovarian and breast cancers show enhanced activation of this kinase (13, 14) . It has been shown that rodent fibroblasts transfected with AURORA-A form tumors in nude mice, indicating that AURORA-A is a cancer susceptibility gene (15) . In addition, some studies have shown that AURORA-A plays an essential role in chromosome segregation and cell division (16, 17) .
Nevertheless, the underlying mechanism by which AURORA-A promotes tumorigenesis remains elusive. Identification of the substrates and further exploration of the signaling pathway linking AURORA-A to other key factors regulating cell growth will provide new insight into understanding tumorigenesis.
Here, we further demonstrate that SPINDLIN1 is highly expressed in ovarian cancer tissues and also promotes cancer cell proliferation and tumor growth. Most importantly, SPINDLIN1 is found to function as an activator of WNT/TCF-4 signaling and promotes the expression of the WNT/TCF-4 targets, C-MYC, CYCLIN D1 and AXIN2. Mutation of the 84 and 99 amino acid sites on SPINDLIN1 could largely abolish its effects on WNT/TCF-4 activity and cancer cell proliferation, suggesting that SPINDLIN1 may promote cancer cell growth through the activation of WNT/TCF-4 signaling. Further analysis suggests that the key functional sites of SPINDLIN1, amino acids Ser 84 and 99, may be candidate phosphorylation sites for AURORA-A. Taken together, our results suggest that SPINDLIN1 promotes cancer cell proliferation by activating the WNT/TCF-4 signaling pathway, and the phosphorylation of Ser84 and Ser99 of SPINDLIN1 may be involved in its effect on WNT/TCF-4 activity. Immunohistochemistry was performed on microarray slides containing 53 ovarian cancer tissues and 4 normal tissues obtained from Chaoying Biotechnology. Another 10 cancer-free ovarian tissues were obtained from 307 Hospital. Tissue sections were deparaffinized by submerging slides in xylene, rehydrated in decreasing concentrations of ethanol, and boiled twice in 0.1 M citrate buffer antigen retrieval solution (pH 6.0) for 5 min (each time). Staining was performed using rabbit anti-SPINDLIN1 antibodies. Signals were detected using the Vectastain Elite ABC kit (Vector Laboratories). Hematoxylin was used for counterstaining.
Materials and methods

2.1．Immunohistochemistry
2.2．Plasmid clones
To generate AURORA-A and SPINDLIN1 expression vectors, GFP-AURORA-A was made by cloning its cDNA into pEGFP-C1. C-MYC-and GFP-SPINDLIN1 were constructed by inserting the open reading frame region of SPINDLIN1 into pcDNA3.1/MYC-HIS (-) and pEGFP-C1 vector, respectively. For lentivirus generation, the C-MYC-tagged human SPINDLIN1 coding sequence was cloned into the pBPLV vector. To purify the protein from bacterial cells, full-length and ten GST-SPINDLIN1 constructs (1: aa 1-59; 2: aa 51-83; 3: aa 51-94; 4: aa 61-94; 5: aa 85-105; 6: aa 85-138; 7: aa 100-138; 8: aa 123-186; 9: aa 175-237; 10: aa 544-647) were made by cloning the corresponding cDNAs into the pGEX-4T-1 vector. For expression of mutant SPINDLIN1 in mammalian cells, wild-type plEGFP-C1-SPINDLIN1 was constructed, and mutants (SPINDLIN1 S84A, S85A, S96A, S99A, and S84/99A) were generated using the QuikChange Site-Directed Mutagenesis Kit (Merck). HeLa, A549, H1299 and HEK293T cell lines were purchased from ATCC. HeLa and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM), and A549 and H1299 cells were grown in RPMI 1640 medium (Sigma). Both media were supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 U/ml penicillin, and 100 μg/ml streptomycin, and all cells were maintained at 37°C in 5% CO 2 . Transfections of the cells were performed using Lipofectamine TM 2000 (Invitrogen) following the manufacturer's instructions.
2.3．Cell culture and transfection
2.4．Antibodies
Rabbit polyclonal anti- 
2.5．Colony forming assay
HeLa cells were stably transfected with expression vectors encoding wild-type SPINDLIN1 or empty vector (pBPLV) using a lentiviral packaging system. The independent clones were cultured and three SPINDLIN1 clones (SC1, SC2, SC3) as well as two control clones (CC1 and CC2) were used for colony formation assay. The cells were plated at 500 cells per well in 6-well plates and the culture medium was replaced every three days. At the end of the incubation, the 
2.6．Cell counting kit-8(CCK-8) cell proliferation assay
Viable cells were examined using the CCK-8 assay (Dojindo). HeLa cells transfected with siRNA-SPINDLIN1 or control oligonucleotide were seeded into 96-well plates at a density of 1× An siRNA sequence used for depleting SPINDLIN1 was purchased from Sigma-Aldrich. The following target sequences were chosen for RNA interference: 5'-GATTCAGCATGGGTGGA AA-3'. An oligonucleotide sequence was used as a negative control (Sigma-Aldrich).
2.9．In vitro invasion assay
HeLa or A549 cells were transfected with pcDNA3.1-MYC/HIS(-)-SPINDLIN1 or pcDNA3.1-MYC/HIS(-). Matrigel (BD Biosciences), diluted 1:6, was added to each Millicell Hanging Cell Culture Insert (PET membrane, 8.0 μm pore size) and polymerized at 37°C for 4 h.
Cells were added to the upper chamber without FBS, and the lower chamber was filled with the culture medium containing 1.5% FBS. After incubation for 36 h, the cells on the Matrigel-coated side of the membrane were removed, and cells on the other side were stained with crystal violet.
The cells migrating through the membrane were counted in 5 randomly selected fields for each sample, and each sample was repeated in three wells.
2.10．Luciferase reporter assay
A549 and H1299 cells were co-transfected using Lipofectamine followed the manufacturer's protocol. The results were analyzed using SOFTMAX ® PRO SOFTWARE (Molecular Devices), and each sample was analyzed in triplicate. Luciferase activity results were normalized to Renilla activity and expressed as the ratio relative to control plasmid activity.
2.11．Immunofluorescence
HeLa cells plated on coverslips were transfected with pEGFP-C1-SPINDLIN1 for 24 h. The cells were treated with 1% Triton X-100, followed by incubation with 10% goat serum for 30 min.
After incubation with the AURORA-A antibody (at a dilution of 1:25) overnight at 4℃, the cells were washed and incubated with TRITC-conjugated goat anti-rabbit IgG diluted 1:50, for 30 min at 37°C. After washing, the cells were finally stained with 4', 6'-diamidino-2-phenylindole (DAPI, 2 μg/ml; Sigma). Microscopic images were acquired using Zeiss LSM 510 META system with a 40× oil objective (Karl Zeiss).
2.12．Immunoprecipitation and immunoblotting analysis
HeLa cells were lysed in RIPA buffer (0.5% sodium deoxycholate, 0.1% SDS, and 1% NP-40) containing protease inhibitor cocktail (Calbiochem). Approximately 500 μg of total cellular protein was incubated with 10 μl of primary antibody for 1 h at 4°C. Then, 20 μl of Protein A/G PLUS-Agarose (Santa Cruz Biotechnology) was added, and the samples incubated overnight at 4°C. For immunoblotting analysis, we followed the previously described methods (2), using anti-AURORA-A and anti-C-MYC antibodies. 
2.13．GST-pulldown assay
GST and GST-fusion proteins were induced in Escherichia coli strain BL21 (DE3) by addition of 1 mM isopropylthiogalactopyranoside (IPTG), and the cultures were maintained at 16°C for 4 h. The proteins were purified using Glutathione Sepharose 4B (Amersham Bioscience) beads according to the manufacturer's instructions. HeLa cells transfected with pEGFP-C1-AURORA-A were harvested after 24 h, and the lysates were incubated with purified GST fusion protein bound to glutathione-agarose beads at 4°C for 4 h. Then the mixture was then boiled, and eluted proteins were separated by SDS-PAGE followed by immunoblotting analysis using anti-AURORA-A and anti-GST antibodies.
2.14．Reverse transcription PCR
Total RNA was extracted with TRIzol reagent (Invitrogen) following the recommended protocol.
The first strand of cDNA was synthesized using oligodT or a random primer (TaKaRa) and then reverse transcribed by M-MLV (TaKaRa). PCR was performed in a final volume of 20 μl using rTaq DNA-polymerase (TaKaRa). The PCR cycle conditions were 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s, finishing with 7 min at 72°C.
β-ACTIN was used as an internal standard. The PCR products were visualized in 1.2% agarose gels by staining with Gel Green (Biotium). The primers for the PCR were as follows: -P]ATP by the method described previously (18) . The proteins were separated by SDS-PAGE, and the gels were analyzed by autoradiography.
Results
SPINDLIN1 is highly expressed in ovarian cancer tissues.
To analyze SPINDLIN1 expression in ovarian cancer tissues, we conducted immunohistochemical analysis using the purified SPINDLIN1 antibody. The samples were obtained from a microarray containing 53 different types of ovarian cancer tissues, including serous papillary cystadenocarcinoma, adenocarcinoma, squamous cell carcinoma and dysgerminoma. Fourteen non-tumor ovarian tissues were also included in the analysis for comparison. The results indicated that SPINDLIN1 is mainly expressed in cancer cell nuclei (Fig.   1A-b, c, d ), whereas no expression was found in normal tissues (Fig. 1A-a) 
SPINDLIN1. In regard to grade II and grade III/IV tissues, high expression of SPINDLIN1 was observed in 12 of 23 and 11 of 24 samples, respectively (Table S1 ). The results showed that grade II and grade III/IV cancer tissues possessed a higher level of SPINDLIN1 expression compared with grade I tissues (Fisher's exact test, p<0.05). These findings corresponded with our first report, which identified SPINDLIN1 as a novel ovarian cancer-related gene and demonstrated that it was overexpressed in ovarian cancer tissues, but not in the normal tissues (3).
SPINDLIN1 promotes cancer cell proliferation and invasion.
To study the effects of SPINDLIN1 on cell proliferation, six independent clones, including four clones of HeLa cells stably expressing SPINDLIN1 (SC1 to SC4) and two control clones (CC1 and CC2) were cultured ( Fig. 2A) . Three SPINDLIN1 clones and two control clones were used in colony forming assays. After 2-3 weeks, the number of colonies of HeLa cells increased from 129.33±24.01 (CC1) and 111.33±7.64 (CC2) to 218.67±32.47 (SC1, N=3, p<0.05), 358.00±44.58 (SC2, N=3, p<0.001) and 405.67±45.08 (SC3, N=3, p<0.001) (Fig. 2B) , showing that SPINDLIN1 promoted cell growth in vitro. To conduct the tumorigenicity assay, each of SPINDLIN1 clones (SC1, SC2, SC3 and SC4), were injected into one flank of 4 nu/nu mice, respectively. CC1 and CC2 were injected into the other flank of mice. Within one month, it became clear that the tumors derived from SPINDLIN1-overexpressing HeLa cells grew faster and were heavier than those produced by control cells (Fig. 2C) . The tumor weight increased from 0.18±0.13 g (CC) to 0.43±0.28 g (SC, N=16, p<0.01). This result showed that SPINDLIN1 accelerated the growth of HeLa tumors. We used RNA interference to deplete SPINDLIN1 in HeLa cells (Fig. S1A, siRNA-SPINDLIN1-1 -11-0440 in the CCK-8 assay (Fig. S1B) . Differences in proliferation appeared beginning on day 2 (N=6, p<0.001). In addition, the colony forming assays also confirmed that the depletion of SPINDLIN1 resulted in reduced colony formation (N=3, p<0.01, Fig. S1C ). These results suggested that SPINDLIN1 depletion slowed the growth of tumor cells.
An in vitro invasion assay demonstrated a significant enhancement of the invasiveness of HeLa and A549 cells transfected with SPINDLIN1 (Fig. 2D) . The number of invasive HeLa cells increased from 88.27±4.20 to 262.33±13.70 (N=3, p<0.001), and that of A549 cells increased from 114.73±12.63 to 322.67±18.77 (N=3, p<0.001). These results showed that SPINDLIN1 contributed both to the proliferation ability and invasiveness of the tumor cells.
SPINDLIN1 promotes activation of WNT/TCF-4 signaling.
Our previous study suggested that SPINDLIN1 might function as a tumor enhancer through activation of the WNT/TCF-4 signaling pathway (19) . Here, we confirmed the direct interaction between SPINDLIN1 and TCF-4 by GST-pulldown assay with β-CATENIN as a positive control and the GST empty vector as negative control (Fig. 3A) . Next, we used a luciferase reporter assay to study the effects of SPINDLIN1 on the activity of the TCF/β-CATENIN-responsive reporter. We found that SPINDLIN1 increased the activity of the pTOPFLASH reporter in both H1299 cells (from 1.07±0.04-fold to 1.72±0.09-fold, N=3, p<0.001) and A549 cells (from 1.05± 0.02-fold to 3.82±0.14-fold, N=3, p<0.001). The activity of the control reporter pFOPFLASH was set as 1.00-fold ( Figure 3B Western blot. We found that their expression levels were substantially enhanced in A549 and H1299 cells transfected with SPINDLIN1 (Fig. 3C-D) . These results suggested that SPINDLIN1 functions as a WNT/TCF-4 signaling pathway activator.
SPINDLIN1 promotes cancer cell proliferation via WNT/TCF-4 activation.
To address the question of whether SPINDLIN1 promotes cancer cell proliferation in a WNT/TCF-4 activation-dependent manner, we set out to analyze the biological function of SPINDLIN1 mutants that have lost their ability to activate the WNT/TCF-4 signaling pathway.
According to our previous bioinformatics and localization study, amino acid sites 84 and 99 were identified to play significant roles in SPINDLIN1's cellular localization and may be involved in its function in the WNT/TCF-4 signaling (19) . Firstly, the GST-pulldown assay demonstrated that the SPINDLIN1 mutation at sites 84 and 99 (SPINDLIN1 84/99 M) decrease the interaction between SPINDLIN1 and TCF-4 (Fig. 4A) . The SPINDLIN1 84/99 M mutant was observed to result in a sharp decrease in the TCF/β-CATENIN-responsive reporter's activity in comparison with wild-type SPINDLIN1 in the luciferase reporter assay (from 5.60±0.62-fold to 1.15±0.01-fold, N=3, p<0.001). The reporter's activity was almost as low as that for the empty vector control (Fig. 4B) . RT-PCR results showed a substantial decline in C-MYC, CYCLIN D1 and AXIN2 expression levels when sites 84 and 99 of SPINDLIN1 were mutated (Fig. 4C) , and Western blot demonstrated that the mutations significantly decreased C-MYC and CYCLIN D1 protein levels (Fig. 4D) . These data showed that mutation of SPINDLIN1 at these sites To study whether the mutations of SPINDLIN1 affects its role in cancer cell proliferation, the SPINDLIN1 double mutant was then transfected into cancer cells, which was then used for colony forming assays and tumorigenicity assays. As shown in Fig. 4E , the mutations caused a 43% reduction in the number of colonies (from 145.67±6.03 to 82.67±6.43, N=3, p<0.001) compared to wild-type, but the numbers were still higher than that observed in cells transfected with the empty vector. The tumorigenicity assay was also performed for HeLa cells stably expressing the mutated or wild-type SPINDLIN1. The tumor growth rate for the mutant-transfected cells was markedly lower than for the wild-type SPINDLIN1, and the weight of mutants' tumors was reduced by 67% (from 0.35±0.11 g to 0.11±0.14 g, N=6, p<0.01, Fig.   4F ). The results suggested that SPINDLIN1 promotes tumor cell proliferation by activating the WNT/TCF-4 signaling pathway.
AURORA-A interacts with and phosphorylates SPINDLIN1 at Ser84 and 99.
Considering SPINDLIN1's oncogenic characteristic in cancer cells and its key functional sites, Ser84 and 99 were suggested to be candidate phosphorylation sites of AURORA-A by bioinformatics analysis. We hypothesized that the function of SPINDLIN1 may be related to AURORA-A, a Ser/Thr kinase that plays a vital role in the initiation of mitotic and G2-M transition and also takes part in many activities associated with carcinogenesis (20, 21) .
AURORA-A is found at the centrosomes during interphase and at spindle poles during mitosis (22, 23) . We first checked the localization of SPINDLIN1 in GFP-SPINDLIN1-expressing HeLa approximately to the same region: they were both found at the centrosome during interphase, at spindle poles from metaphase to telophase, and at the microtubules (MTs) of the central body during cytokinesis (Fig. 5A) . The results suggested that the biological functions of SPINDLIN1 and AURORA-A might be related.
To confirm the physical association between AURORA-A and SPINDLIN1 in vitro, we performed a GST-pulldown assay (Fig. 5B) . Coomassie-stained gels showed that recombinant GST (used as a negative control) was expressed and purified with the similar efficiency as the GST-SPINDLIN1 fusion protein. Then, cellular lysates containing GFP-AURORA-A were incubated with purified GST-SPINDLIN1 or GST. Western blot showed that GFP-tagged AURORA-A interacted with GST-SPINDLIN1, whereas band was not detected in the sample incubated with GST alone. These results demonstrated their direct interaction in vitro.
We used co-immunoprecipitation assays to investigate whether AURORA-A interacts with SPINDLIN1 in vivo (Fig. 5C ). After co-transfection, HeLa cells with ectopic expression of GFP-AURORA-A and C-MYC-SPINDLIN1 were lysed, and the lysates were immunoprecipitated using mouse anti-C-MYC antibody. The precipitates were analyzed by Western blot. We observed an AURORA-A band, but this band was absent in the precipitates (Fig. 5D, top panel) . Meanwhile, we found that the kinase phosphorylated fragment 3 (amino acids 51-94) and fragment 6 (amino acids 85-138) of SPINDLIN1. We then narrowed down the phosphorylation locations to amino acids 61-94 and 85-105 (Fig. 5D, middle   panel) . To confirm the specific phosphorylation sites, we replaced serines with alanines at S84, S85, S96 and S99 of SPINDLIN1 to generate S-A mutants. The kinase assay showed a lack of phosphorylation of the S84A and S99A mutants, demonstrating that these sites were the phosphorylation sites (Fig. 5D, bottom panel) . The results demonstrated that SPINDLIN1 interacts with AURORA-A, and its functional sites were phosphorylated by this kinase.
Discussion
SPINDLIN1 was first identified as a new member of the SPIN/SSTY gene family and was implicated in ovarian cancers. Its expression is markedly up-regulated in ovarian cancer cells and other kinds of cancer cells. We have reported that the constitutive expression of SPINDLIN1 contributes to the malignant transformation of NIH3T3 cells (4). In our previous study, we demonstrated that SPINDLIN1 is involved in metaphase arrest and could affect chromosomal stability. SPINDLIN1 protein is dynamically distributed along mitotic spindle tubulins. We also showed that the overexpression of SPINDLIN1 can induce cell cycle delay in metaphase and cause chromosomal instability (5). Nevertheless, the molecular mechanisms underlying the oncogenic role of SPINDLIN1 are still largely unknown.
There seems to be a discrepancy in that SPINDLIN1 could cause a delay in mitosis and also cause chromosome instability (2, 5), but our data presented here confirm the fact that SPINDLIN1 stimulates cell growth. In fact, the two phenomena are not completely contradictory.
Indeed, cell cycle delay might lead to defects in mitotic spindle organization or DNA separation, 
ultimately resulting in cell apoptosis. However, it is possible that chromosomal combination takes place in some cells overexpressing SPINDLIN1, which could help those cells escape cell apoptosis and obtain a selective growth advantage. Consequently, those cells undergoing apoptosis overcome the negative influence of SPINDLIN1 and finally acquire an increased growth rate. This possibility may be one explanation for why SPINDLIN1 overexpression induces tumorigenesis.
Accumulating evidence has suggested that the WNT/β-CATENIN signaling pathway plays an important role in tumorigenesis and development (18, (24) (25) (26) . Many factors have been identified as co-transcription factors in this signaling pathway. They are known to bind TCF-4 or β-CATENIN and function as transcription co-activators or inhibitors (27) (28) (29) . In our previous study, we found that SPINDLIN1 interacts with TCF-4 and activates its activity (19) , suggesting that SPINDLIN1 might promote cancer cell proliferation via this signaling pathway. Here, we have confirmed the existence of an interaction between these two molecules in cancer cells.
Ectopic expression of SPINDLIN1 promotes the activity of a TCF/β-CATENIN-responsive reporter and enhances the expression levels of C-MYC, CYCLIN D1 and AXIN2, the targets of the WNT/TCF-4 signaling pathway. Amino acid sites 84 and 99 of SPINDLIN1 were shown to be important for SPINDLIN1's nuclear localization in our previous study (19) . The mutation of these two sites results in the abrogation of the nuclear localization of SPINDLIN1, which instead is localized diffusely throughout the cell. Therefore, we hypothesized that the two sites could be It has been reported that ectopic expression of AURORA-A up-regulates telomerase activity and increases C-MYC expression in human ovarian and breast cancer cells (15, 30, 31) .
Knocking down C-MYC expression by RNA interference suppressed AURORA-A-stimulated telomerase activity (32). Nevertheless, the mechanism by which AURORA-A up-regulates C-MYC remains unclear. In this study, we have preliminarily discussed the possible mechanism of AURORA-A. We found that SPINDLIN1 interacts with AURORA-A and is a phosphorylated substrate of the kinase. In addition, the function of the phosphorylated sites of SPINDLIN1 has been demonstrated here. Therefore, we propose that the effects of AURORA-A on tumorigenesis may be related to WNT/TCF-4 signaling, which is mediated by phosphorylation of the functional sites of SPINDLIN1. However, more research will be needed to investigate this complex process.
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